Alpha 2.0
Login Register
» Authors » Gemma Bruera

Gemma Bruera

Explore the profile of Gemma Bruera including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 307
Followers 0
Related Specialties
Oncology
General Medicine
General Surgery
Top 10 Co-Authors
Enrico Ricevuto
Corrado Ficorella
Katia Cannita
Stefano Guadagni
Roberto Vicentini
Donatella Sarti
Marco Clementi
Giammaria Fiorentini
Antonella Dal Mas
Aldo Victor Giordano
Published In
Oncotarget
BMC Cancer
Int J Oncol
Clin Colorectal Cancer
Biomed Res Int
Affiliations
Soon will be listed here.
Recent Articles
11.
Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study
Guadagni S, Fiorentini G, Mambrini A, Masedu F, Valenti M, Mackay A, et al.
Oncotarget . 2019 Jun; 10(39):1-13. PMID: 31231460
Background: Innovative systemic treatments and loco-regional chemotherapy by hypoxic pelvic perfusion (HPP) have been proposed for unresectable recurrent rectal cancer (URRC). Regorafenib and trifluridine-tipiracil reported significantly increased PFS 1.9-2.0 months,...
12.
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
Bruera G, Massacese S, Pepe F, Malapelle U, Dal Mas A, Ciacco E, et al.
Ther Adv Med Oncol . 2019 Jun; 11:1758835919846421. PMID: 31205502
Background: Intensive triplet chemotherapy/bevacizumab significantly increased metastatic colorectal cancer (MCRC) outcome. This phase II study investigated the safety/activity of FIr-C/FOx-C triplet/cetuximab (CET) in first-line wild-type and the prediction of individual...
13.
Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: a retrospective study
Guadagni S, Fiorentini G, Palumbo P, Masedu F, Ricevuto E, Bruera G, et al.
Minerva Chir . 2019 May; 74(4):304-312. PMID: 31062943
Background: Patients with unresectable recurrent rectal cancer that progresses after systemic chemotherapy and radiotherapy may be candidates for palliation with hypoxic pelvic perfusion (HPP). The aim of this observational retrospective...
14.
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study
Bruera G, Massacese S, Candria S, Galvano A, Manetta R, Giordano A, et al.
Oncotarget . 2018 Aug; 9(61):31861-31876. PMID: 30159128
Background: Gemcitabine/nab-paclitaxel and FOLFIRINOX demonstrated significantly increased survival compared with gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): objective response rate (ORR) 23 and 31.6%, progression-free survival (PFS) 5.5 and 6.4...
15.
, and mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy
Bruera G, Pepe F, Malapelle U, Pisapia P, Dal Mas A, Di Giacomo D, et al.
Oncotarget . 2018 Jun; 9(41):26279-26290. PMID: 29899858
Background: First line triplet chemotherapy/BEV significantly improved clinical outcome of MCRC. mutations were evaluated by next generation sequencing (NGS) in MCRC patients treated with first line FIr-B/FOx. Methods: exons 2-4...
16.
Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer
Bruera G, Massacese S, Galvano A, Dal Mas A, Guadagni S, Calvisi G, et al.
Oncotarget . 2018 May; 9(29):20339-20350. PMID: 29755655
Introduction: Proper administration timing, dose-intensity, efficacy/toxicity ratio of triplet docetaxel (DTX), 5-fluorouracil (5-FU), and oxaliplatin (OXP) should be improved to safely perform three-drugs intensive first line in advanced gastric cancer...
17.
Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer
Bruera G, Di Staso M, Bonfili P, Galvano A, Manetta R, Coletti G, et al.
Oncotarget . 2018 May; 9(25):17906-17914. PMID: 29707156
Introduction: Proper administration timing, dose-intensity, efficacy/toxicity ratio of oxaliplatin added to fluoropyrimidin should be improved to safely perform two-drugs intensive preoperative chemoradiotherapy in locally advanced rectal cancer (LARC). This dose-finding...
18.
KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease
Tessitore A, Bruera G, Mastroiaco V, Cannita K, Cortellini A, Cocciolone V, et al.
Hum Pathol . 2018 Feb; 74:178-182. PMID: 29409955
We describe a metastatic colorectal cancer patient, treated with first-line 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIr-BFOx) therapy, with aggressive and resistant disease. KRAS, NRAS, BRAF, and PI3KCA were analyzed in...
19.
Effects of Chemotherapy in Patients with Concomitant Aortic Aneurysm and Malignant Disease
Leopardi M, Di Marco E, Musilli A, Ricevuto E, Bruera G, Ventura M
Ann Vasc Surg . 2017 Jul; 45:268.e13-268.e20. PMID: 28739458
Background: The aim of the study is to present the results in a consecutive series of patients affected by aortic abdominal aneurysm and to underline the aneurysmal growth and evolution...
20.
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy
Bruera G, Russo A, Galvano A, Rizzo S, Ricevuto E
Oncotarget . 2017 Jan; 8(23):37875-37883. PMID: 28053287
Introduction: Bevacizumab addiction to triplet chemotherapy, according to FIr-B/FOx schedule, as first-line treatment in young-elderly metastatic colorectal CANCER (MCRC) patients may be more effective. Tailored treatments show worse clinical outcome...